AN2 Therapeutics announced positive results from two studies evaluating its oral CPSF3 inhibitor, AN2-502998, for the treatment of chronic Chagas disease. A 28-day nonhuman primate study showed that 100% of treated animals achieved parasite elimination that was maintained through four months. Additionally, a Phase 1 first-in-human study demonstrated that the compound was well tolerated and achieved plasma exposures at or above nonhuman primate efficacy thresholds.